$136 Million is the total value of Prosight Management, LP's 29 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | New | ALLERGAN PLC | $16,031,000 | – | 98,000 | +100.0% | 11.79% | – |
| MGNX | New | MACROGENICS INC | $11,546,000 | – | 607,696 | +100.0% | 8.49% | – |
| CDTX | New | CIDARA THERAPEUTICS INC | $11,206,000 | – | 1,647,879 | +100.0% | 8.24% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $9,469,000 | – | 678,793 | +100.0% | 6.96% | – |
| SBRA | New | SABRA HEALTH CARE REIT INC | $7,547,000 | – | 402,057 | +100.0% | 5.55% | – |
| CNC | New | CENTENE CORP DEL | $7,162,000 | – | 71,000 | +100.0% | 5.27% | – |
| CMRX | New | CHIMERIX INC | $6,846,000 | – | 1,478,519 | +100.0% | 5.04% | – |
| AKAOQ | New | ACHAOGEN INC | $6,132,000 | – | 570,920 | +100.0% | 4.51% | – |
| QURE | New | UNIQURE NV | $5,578,000 | – | 284,717 | +100.0% | 4.10% | – |
| AFAM | New | ALMOST FAMILY INC | $5,012,000 | – | 90,548 | +100.0% | 3.69% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $4,896,000 | – | 172,897 | +100.0% | 3.60% | – |
| QTNT | New | QUOTIENT LTD | $4,616,000 | – | 932,523 | +100.0% | 3.40% | – |
| RXDX | New | IGNYTA INC | $4,575,000 | – | 171,352 | +100.0% | 3.36% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $4,055,000 | – | 506,852 | +100.0% | 2.98% | – |
| ELGX | New | ENDOLOGIX INC | $3,509,000 | – | 655,815 | +100.0% | 2.58% | – |
| RDUS | New | RADIUS HEALTH INC | $3,495,000 | – | 110,000 | +100.0% | 2.57% | – |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $3,194,000 | – | 178,453 | +100.0% | 2.35% | – |
| AVEO | New | AVEO PHARMACEUTICALS INC | $2,951,000 | – | 1,057,690 | +100.0% | 2.17% | – |
| New | NABRIVA THERAPEUTICS PLC | $2,939,000 | – | 491,395 | +100.0% | 2.16% | – | |
| CLVS | New | CLOVIS ONCOLOGY INC | $2,720,000 | – | 40,000 | +100.0% | 2.00% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $2,534,000 | – | 301,349 | +100.0% | 1.86% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,069,000 | – | 44,600 | +100.0% | 1.52% | – |
| DXCM | New | DEXCOM INC | $1,790,000 | – | 31,198 | +100.0% | 1.32% | – |
| New | ON ASSIGNMENT INCput | $1,652,000 | – | 25,700 | +100.0% | 1.22% | – | |
| LPCN | New | LIPOCINE INC NEW | $1,283,000 | – | 373,101 | +100.0% | 0.94% | – |
| CFMS | New | CONFORMIS INC | $952,000 | – | 400,000 | +100.0% | 0.70% | – |
| NVLNF | New | NOVELION THERAPEUTICS INC | $925,000 | – | 296,488 | +100.0% | 0.68% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $878,000 | – | 26,916 | +100.0% | 0.65% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $407,000 | – | 12,000 | +100.0% | 0.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.